The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s anti-parkinson drugs market report forecasts the anti-parkinson drugs market size to grow to $12.37 Billion by 2027, with a CAGR (compound annual growth rate) of almost 5%.

Learn More On The Anti-Parkinson Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Anti-Parkinson Drugs Market Size Forecast
The global anti-parkinson drugs market is expected to grow from $9.64 billion in 2022 to $10.23 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anti-parkinson drugs market size is expected to grow to $12.37 billion in 2027 at a CAGR of 4.9%.

North America held the largest anti-parkinson drugs market share, and Middle East was the fastest-growing region in 2022.

Key Anti-Parkinson Drugs Market Driver ­– Increase In Geriatric Population And Surging Cases Of Parkinson’s Disease
For instance, in June 2020, according to a study by the United Nations, the total number of people age 80 and above is expected to increase from 143 million in 2019 to over 426 million in 2050. Also, in February 2020, Harvard University, a US-based academic university specializing in teaching, learning, and research, will announce that, according to the Parkinson’s Foundation, there are more than 10 million people living with Parkinson’s disease globally, and this year, there will be close to one million cases in the United States. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease are therefore driving market growth.

Request for A Sample Of The Global Anti-Parkinson Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Key Anti-Parkinson Drugs Market Trend – Increasing Government And Corporate Investment In Parkinson’s Disease Drug R&D
Increased government and corporate investment in Parkinson’s disease drug R&D is a major trend in the anti-Parkinson drugs market. For instance, in August 2022, the Parkinson’s Foundation, a US-based national organization that provides funding for research and educational resources, will make a $5.7 million investment in 33 projects to speed up cutting-edge research on Parkinson’s disease (PD). Through research grants, the Foundation helps scientists carry out creative studies on numerous PD-related topics in an effort to develop novel therapies, treatments, and ultimately a cure for the 10 million people who suffer from this crippling neurological condition worldwide. Hence, increasing investments in Parkinson’s drug development are expected to drive the market for anti-Parkinson’s drugs.

Anti-Parkinson Drugs Market Segment
1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-Inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Anti-Parkinson Drugs Market Major Players and Strategies
Major players in the anti-parkinson drugs market are GlaxoSmithKline PLC., Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc., Sun Pharma, Wockhardt, Dr. Reddy’s, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC., Zambon Pharmaceuticals, and M Somerset Pharmaceuticals Inc., and Wockhardt.

The Anti-Parkinson Drugs Global Market Report 2023 covers regional data on anti-parkinson drugs market size, anti-parkinson drugs market trends and drivers, opportunities, strategies, and anti-parkinson drugs market competitor analysis. The countries covered in the anti-parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Anti-parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.

View More Reports Related To The Anti-Parkinson Drugs Market –
AntiHypertensive Drugs Global Market Report 2023
Drugs For Erectile Dysfunction Global Market Report 2023
Drugs For Hormonal Replacement Therapy Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: